BPC-157: Dosing Protocols

Research Dosing Disclaimer#

The dosing information below is derived from research studies and is provided for educational purposes only. BPC-157 is not approved for human use, and no official dosing guidelines exist.

Dose-Response Data#

We synthesized animal dose–response evidence for BPC‑157 across multiple models, reporting weight‑normalized doses, routes, timing, and outcomes. A structured summary is embedded for quick reference.

Muscle transection (healing). In rats with transected quadriceps, daily intraperitoneal BPC‑157 at 10 mg/kg, 10 ng/kg, or 10 pg/kg began 30 minutes post‑surgery. Healing showed a clear graded response: by day 72, bridge formation and gross muscle recovery reached about 90% at 10 mg/kg, ~80% at 10 ng/kg, and ~45% at 10 pg/kg, all superior to saline (~10%). Histology and biomechanics improved concordantly; contractures were prevented (p < 0.001). Thus, higher systemic doses yielded greater functional recovery in this model.

Post‑incisional pain (analgesia). In a rat plantar incision model, single intraperitoneal doses of 10, 20, or 40 μg/kg produced an early, dose‑dependent increase in mechanical withdrawal thresholds at 2 h; the effect waned by 6 h. In the formalin test, BPC‑157 reduced phase‑1 (acute) flinches dose‑dependently but did not affect phase‑2 (inflammatory/central sensitization), unlike morphine. A delayed analgesic signal reappeared at day 4 for 40 μg/kg. Group body weights were ~262–272 g, confirming per‑kg normalization.

Gastric ulcer models (protection/healing). In rats, intramuscular and intragastric dosing at 200, 400, and 800 ng/kg reduced ulcer area and accelerated healing; efficacy increased with dose, and intramuscular delivery exceeded intragastric. Reported inhibition ratios ranged ~45.7%–65.6% across models, with ~60%–66% at 800 ng/kg i.m. Continuous dosing facilitated epithelial and granulation tissue restoration.

Colocutaneous fistula (closure). In rats, daily intraperitoneal BPC‑157 at 10 μg/kg or 10 ng/kg, started 30 minutes after surgery (final dose 24 h pre‑assessment), and an oral regimen via drinking water (0.16 μg/mL; ~12 mL/rat) improved early healing (days 3–5) and enabled closure by day 28, outperforming controls and standard comparators. Both μg/kg and ng/kg regimens were effective; the excerpted data did not specify superiority between them.

Pharmacokinetics informing dose ranges. In rats, single intravenous 20 μg/kg and intramuscular 20, 100, or 500 μg/kg doses (and 100 μg/kg IM daily ×7) showed linear exposure; IM bioavailability was ~14%–19% in rats and ~45%–51% in beagles. These PK data contextualize mid‑μg/kg exposures commonly used in efficacy studies and the short plasma half‑life after IV dosing (<30 min).

Across models, BPC‑157 demonstrates efficacy from pg/kg to mg/kg in rodents, with multiple studies showing either clear dose‑response (e.g., muscle transection) or effective activity at both low (ng/kg) and higher (μg/kg) doses (e.g., fistula closure). Analgesic effects appear dose‑related acutely but short‑lived, with limited impact on inflammatory/central sensitization phases. Gastric protection shows increasing benefit with higher ng/kg doses and greater effect via i.m. vs oral routes. However, dose–response curves are often sparse (few dose levels), and head‑to‑head superiority between adjacent doses is not always quantified. Translational relevance is limited by heterogeneous models, routes, and predominantly rodent species.

Citations: muscle transection dose–response; incisional pain dose–dependence; gastric ulcer ng‑range dose‑response and route differences; fistula healing at ng vs μg regimens and oral water regimen; PK dose context and bioavailability.

Administration Routes#

We compared subcutaneous (SC), oral, intramuscular (IM), and topical routes for BPC‑157 with emphasis on bioavailability and route‑specific pharmacokinetics, drawing on preclinical pharmacokinetic (PK) studies and route‑of‑administration reports. Where evidence was not available, we indicate gaps.

Intramuscular (IM)

• Absorption and bioavailability: In rats, absolute IM bioavailability is approximately 14–19%; in beagle dogs it is higher, approximately 45–51%. Tmax is rapid (rats ~3 min; dogs ~6–9 min), indicating very fast absorption from muscle. Dose proportionality and linear PK are reported across tested IM doses.
• Distribution and elimination: Parent peptide concentrations decline rapidly; parent is typically undetectable by 4 h post‑dose. Reported elimination half‑life for parent is short and under 30 min (rats single‑dose t1/2 ~15 min; dogs IV t1/2 ~5 min; repeated IM in dogs reported apparent t1/2 ~20 min). Tissue radioactivity peaks later and persists longer than plasma parent, reflecting metabolites and tissue distribution.
• Excretion and metabolism: Radiolabeled studies show primary excretion via urine and bile. BPC‑157 is rapidly metabolized into smaller peptide fragments and amino acids; multiple metabolites (M1–M6) are detected across plasma, urine, bile, and feces.

Subcutaneous (SC)

• Quantitative PK: We did not find validated quantitative PK or bioavailability data for SC dosing in the retrieved sources. No Tmax/Cmax/t1/2 are reported for SC.
• Qualitative notes: Although SC use is discussed in secondary sources for peptides generally, we did not retrieve route‑specific BPC‑157 SC PK data; this remains an evidence gap.

Oral (per‑oral)

• Stability and feasibility: Multiple reviews characterize BPC‑157 as native to and stable in human gastric juice, supporting feasibility of oral dosing.
• Preclinical efficacy by oral route: Rat studies report effective outcomes when given orally (e.g., in drinking water) for gastrointestinal and tissue healing, indicating biologic activity after oral administration. However, these studies do not report quantitative oral PK (bioavailability, Tmax, Cmax, t1/2).
• PK knowledge gap: No oral bioavailability or plasma PK parameters were identified in the dedicated PK study; thus, route‑specific oral systemic exposure remains unquantified.

Topical and local administration

• Topical use: Preclinical literature reports local application (e.g., creams) improving skin and burn wound healing. Quantitative dermal absorption or systemic PK after topical dosing was not reported in the sources retrieved.
• Intra‑articular: A clinical case series noted durable symptom improvement after a single intra‑articular injection, consistent with local action, but without PK data.

Cross‑route considerations and pharmacokinetic themes

• Rapid systemic clearance of parent: Across IV/IM studies, the parent peptide shows short plasma half‑life (<30 min) with rapid loss from circulation; radiolabel persists as metabolites, producing longer total radioactivity signals than parent.
• Distribution and excretion: Early and prominent distribution to kidney and liver with dominant urinary and biliary excretion are consistent findings.
• Evidence hierarchy: Numeric PK exists for IM (and IV) in rats and dogs. For SC, oral, and topical, current evidence is largely qualitative/preclinical, with oral stability and efficacy demonstrated in animals but without quantified systemic bioavailability. No human PK data were found in the retrieved sources.

Practical comparison by route

• IM: Provides rapid systemic exposure with measurable bioavailability (species‑dependent), very fast Tmax (minutes), and short parent half‑life; metabolism to fragments with urinary/biliary excretion.
• SC: No validated PK; systemic exposure and bioavailability unknown. Evidence gap.
• Oral: Biologically active in animal models and stable in gastric juice; quantitative oral PK not reported; systemic exposure after oral dosing remains to be defined.
• Topical/local: Effective for local wound models; systemic absorption and PK not characterized. Intra‑articular reports suggest local benefit without PK quantification.

Conclusions

• Among the requested routes, IM has the clearest pharmacokinetic characterization: low‑to‑moderate absolute bioavailability (higher in dogs than rats), very rapid absorption (Tmax minutes), short t1/2 for the parent (<30 min), rapid metabolism, and renal/biliary excretion.
• Oral and topical routes show preclinical efficacy and feasibility (supported by gastric stability for oral), but lack quantified bioavailability or PK parameters. SC PK data are presently lacking in the retrieved evidence. No human PK data were identified. Future work should quantify SC/oral/topical bioavailability and route‑specific PK, and evaluate human PK to enable rigorous route comparisons.

Human-Equivalent Dosing#

• General allometric scaling used in the literature. Practical interspecies dose conversion relies on BSA/Km normalization: mg/kg × Km = mg/m^2; HED (mg/kg) = Animal dose × (Km_animal/Km_human). Example Km values commonly used: rat ≈ 6, human (60 kg) ≈ 37. Alternate allometry uses weight exponents (e.g., HED = Animal dose × (W_animal/W_human)^0.33). These methods are documented and are the standard references authors invoke when saying “converted based on BSA.”

• Utility and limitations. Retrospective analyses show BSA scaling can approximate clinical dose ranges for small‑molecule oncology drugs but caution that it is imprecise and modality‑dependent; mechanistic PK/PD or PBPK models are preferred when available. This context is often cited to justify BSA/Km as an early translational tool rather than a definitive clinical‑dose selector.

Illustrative calculation (using cited Km approach). If an efficacious rat dose were 10 µg/kg, the HED for a 60‑kg human by Km ratio is: HED (µg/kg) = 10 × (6/37) ≈ 1.62 µg/kg, which corresponds to ~97 µg/person/day. This matches the scale of the 200 µg/person/day target that He et al. referenced when bracketing rat doses at 20 µg/kg by BSA.

Embedded summary table.

Evidence Gaps#

• No human dose-finding studies have been completed
• Allometric scaling from animal models has inherent limitations
• Route-specific bioavailability data in humans is absent
• Optimal treatment duration has not been established

Tools & Resources#

Calculate your exact dose -- Use the Dosing Calculator to convert vial concentrations to injection volumes for BPC-157.

Building a multi-peptide protocol? -- Try the Protocol Schedule Builder to plan your research timeline with BPC-157 alongside other peptides.

Estimate monthly cost -- Use the Cost Calculator to budget your BPC-157 protocol based on dose and vial size.

Related Dosing Guides#

• GHK-Cu Dosing Protocols -- Frequently combined with BPC-157 for tissue repair
• TB-500 Dosing Protocols -- The most common BPC-157 stacking partner

Compare BPC-157#

• BPC-157 vs GHK-Cu -- Healing peptide comparison
• BPC-157 vs TB-500 -- The classic healing stack breakdown
• BPC-157 vs Semaglutide -- GI protection vs GLP-1 therapy

Related Reading#

• BPC-157 overview and research guide
• BPC-157 side effects profile
• BPC-157 research evidence